申请人:Abbott Laboratories
公开号:US05026729A1
公开(公告)日:1991-06-25
Compounds having 5- and 12-lipoxygenase inhibitory activity have the structure ##STR1## where A is straight or branched divalent alkylene of from one to four carbon atoms, R.sub.1 is methyl, amino, or alkylamino of from one to six carbon atoms and the substituent group R.sub.2 is C.sub.1 -C.sub.2 alkyl. The group R.sub.3 is one or more substituents selected from hydrogen, alkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, thioalkoxy of from one to six carbon atoms, halogen, cyano, and trihalomethyl, and R.sub.4 is one or more substituents selected from hydrogen, alkyl of from one to six carbon atoms, alkoxy of from one to six carbon atoms, thioalkoxy of from one to six carbon atoms, hydroxy, halogen, cyano, and trihalomethyl, with the proviso that when R.sub.1 is amino and A is >CHCH.sub.3, R.sub.3 and R.sub.4 may not both be hydrogen. The group designated M is hydrogen, a pharmaceutically acceptable cation, or a metabolically cleavable group. Pharmaceutical compositions and a method of inhibiting 5- and 12-lipoxygenase activity are also disclosed.
具有5-和12-脂氧酶抑制活性的化合物具有以下结构##STR1##其中A是直链或支链的二价碳原子数为1至4的烷基,R.sub.1是甲基、氨基或碳原子数为1至6的烷基氨基,取代基R.sub.2是C.sub.1-C.sub.2烷基。基团R.sub.3是氢、碳原子数为1至6的烷基、碳原子数为1至6的烷氧基、碳原子数为1至6的硫代烷氧基、卤素、氰基和三卤甲基中选择的一个或多个取代基,R.sub.4是氢、碳原子数为1至6的烷基、碳原子数为1至6的烷氧基、碳原子数为1至6的硫代烷氧基、羟基、卤素、氰基和三卤甲基中选择的一个或多个取代基,但当R.sub.1为氨基且A为>CHCH.sub.3时,R.sub.3和R.sub.4不能同时为氢。指定为M的基团是氢、药用可接受的阳离子或代谢可裂解基团。还公开了制备药物组合物和抑制5-和12-脂氧酶活性的方法。